BR112018009361A8 - composições e métodos para o tratamento de doenças autoimunes e de câncer - Google Patents

composições e métodos para o tratamento de doenças autoimunes e de câncer

Info

Publication number
BR112018009361A8
BR112018009361A8 BR112018009361A BR112018009361A BR112018009361A8 BR 112018009361 A8 BR112018009361 A8 BR 112018009361A8 BR 112018009361 A BR112018009361 A BR 112018009361A BR 112018009361 A BR112018009361 A BR 112018009361A BR 112018009361 A8 BR112018009361 A8 BR 112018009361A8
Authority
BR
Brazil
Prior art keywords
methods
cancer
compositions
treatment
autoimmune diseases
Prior art date
Application number
BR112018009361A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018009361A2 (en
Inventor
Sun Jingwei
Wang Jun
Chen Lieping
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of BR112018009361A2 publication Critical patent/BR112018009361A2/en
Publication of BR112018009361A8 publication Critical patent/BR112018009361A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
BR112018009361A 2015-11-10 2016-11-09 composições e métodos para o tratamento de doenças autoimunes e de câncer BR112018009361A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253437P 2015-11-10 2015-11-10
US62/253,437 2015-11-10
PCT/US2016/061086 WO2017083354A1 (en) 2015-11-10 2016-11-09 Compositions and methods for treating autoimmune diseases and cancers

Publications (2)

Publication Number Publication Date
BR112018009361A2 BR112018009361A2 (en) 2018-11-13
BR112018009361A8 true BR112018009361A8 (pt) 2019-02-26

Family

ID=58695157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009361A BR112018009361A8 (pt) 2015-11-10 2016-11-09 composições e métodos para o tratamento de doenças autoimunes e de câncer

Country Status (13)

Country Link
US (2) US20180318419A1 (https=)
EP (2) EP4512827A3 (https=)
JP (4) JP6924495B2 (https=)
KR (1) KR102810368B1 (https=)
CN (2) CN116510015A (https=)
AU (2) AU2016354100B2 (https=)
BR (1) BR112018009361A8 (https=)
CA (1) CA3002095A1 (https=)
HK (1) HK1259294A1 (https=)
MX (2) MX2018005830A (https=)
RU (1) RU2761980C2 (https=)
TW (2) TWI847955B (https=)
WO (1) WO2017083354A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017330346C1 (en) 2016-09-21 2025-03-06 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
CN113138273B (zh) * 2020-01-17 2024-06-18 孟民杰 一种应用于肺癌快速筛查及免疫靶向治疗检测的试剂盒及其用途
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof
CN113817057B (zh) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 一种抗siglec15抗体及其应用
CN114525256A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
EP4032973B1 (en) * 2021-01-21 2023-07-19 Guizhou Sinorda Biotechnology CO., Ltd. Modified t cells for adoptive immunotherapy
CA3204359A1 (en) * 2020-12-08 2022-06-16 Guizhou Sinorda Biotechnology Co. Ltd. Modified t cells for adoptive immunotherapy
CN114657132A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15靶向抑制因子的多能干细胞及其衍生物与应用
IL305409A (en) * 2021-02-23 2023-10-01 Shanghai Jemincare Pharmaceuticals Co Ltd Preparation of SIGLEC-15 binding protein and its use
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN114751973B (zh) * 2021-03-12 2024-02-20 百奥赛图(北京)医药科技股份有限公司 Siglec15基因人源化非人动物的构建方法和应用
CN116983412A (zh) * 2023-08-04 2023-11-03 南通大学 Siglec-15-SE超增强子在制备治疗肿瘤的产品中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
ATE275415T1 (de) * 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
EP2322185A3 (en) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US20100028321A1 (en) * 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
JPWO2009048072A1 (ja) * 2007-10-11 2011-02-17 第一三共株式会社 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
RU2539790C2 (ru) 2009-04-09 2015-01-27 Дайити Санкио Компани, Лимитед АНТИТЕЛО ПРОТИВ Siglec-15
JP5998060B2 (ja) * 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
BR112013002940A2 (pt) * 2010-08-13 2019-09-24 Baylor Res Institute adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
JP2013543382A (ja) * 2010-10-05 2013-12-05 第一三共株式会社 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
ES2908046T3 (es) * 2011-09-09 2022-04-27 Medimmune Ltd Anticuerpos anti-siglec-15 y usos de los mismos.
EP2610263A1 (de) * 2011-12-30 2013-07-03 Brossmer, Reinhard Sialinsäure-Dimere
WO2015054600A2 (en) * 2013-10-10 2015-04-16 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
PL3129067T3 (pl) * 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących

Also Published As

Publication number Publication date
JP2023096078A (ja) 2023-07-06
AU2016354100A1 (en) 2018-06-21
RU2761980C2 (ru) 2021-12-14
EP3373962A1 (en) 2018-09-19
EP4512827A2 (en) 2025-02-26
HK1259294A1 (zh) 2019-11-29
RU2018121050A3 (https=) 2020-03-13
JP2021167353A (ja) 2021-10-21
KR102810368B1 (ko) 2025-05-19
MX2018005830A (es) 2018-11-12
AU2016354100B2 (en) 2023-11-30
TW201729841A (zh) 2017-09-01
US20180318419A1 (en) 2018-11-08
EP3373962A4 (en) 2020-02-19
MX2023012451A (es) 2023-10-31
JP2018533591A (ja) 2018-11-15
WO2017083354A1 (en) 2017-05-18
CN116510015A (zh) 2023-08-01
JP6924495B2 (ja) 2021-08-25
US20220168419A1 (en) 2022-06-02
JP2025156500A (ja) 2025-10-14
CA3002095A1 (en) 2017-05-18
TW202330019A (zh) 2023-08-01
RU2018121050A (ru) 2019-12-13
AU2024201282A1 (en) 2024-03-14
TWI847955B (zh) 2024-07-11
EP4512827A3 (en) 2025-04-30
KR20180073691A (ko) 2018-07-02
CN108430498A (zh) 2018-08-21
BR112018009361A2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
BR112018009361A8 (pt) composições e métodos para o tratamento de doenças autoimunes e de câncer
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
EA201991214A1 (ru) Антитела против pd-1 и их композиции
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
MX2018001387A (es) Anticuerpo de dominio simple y proteinas derivadas del mismo contra ligando de muerte programada (pdl1).
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112015005772A2 (pt) método para a intensificação de imunoterapias específicas no tratamento de câncer
GEAP202114828A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
BR112016000853A2 (pt) métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
BR112017027549A2 (pt) anticorpo para cd40
MX2016011072A (es) Derivado de pirazol amida.
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
BR112016019825A2 (pt) anticorpos do fator bb do complemento
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112018010705A8 (pt) vacinação com o domínio mica/b alfa 3 para o tratamento de câncer
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]